ClinicalTrials.gg
CompletedNCT01381094Updated Jul 1, 2022Results posted

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Phase 2 interventional study of AKB-6548 and Placebo in Anemia and Kidney Disease, sponsored by Akebia Therapeutics. Completed at 28 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2022-07-01.

Sponsored by Akebia Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
13th of 27
93 · median 60
Started
2011
the only one that year
Phase 2
8 of 27
none open now
Registered
2nd of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 13th largest by enrollment, is the only one that started in 2011, is one of 8 in phase 2, and was the 2nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the dose response (efficacy), pharmacodynamic response, pharmacokinetics, safety, and tolerability of orally administered AKB-6548 in pre-dialysis participants with anemia with repeat dosing for 42 days.

03

Conditions studied

  • Anemia
  • Kidney Disease

Keywords

  • anemia
  • chronic kidney disease
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • safety
  • efficacy
  • tolerability
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • 18 to 79 years of age, inclusive
  • Chronic Kidney Disease ( \<60 mL/min), not yet on dialysis
  • (Hgb) ≤ 10.5 g/dL
  • Transferring saturation ≥ 20%
  • Ferritin ≥ 50 ng/mL

Key Exclusion Criteria:

  • >42
  • Red blood cell transfusion within 12 weeks
  • Androgen therapy within the previous 21 days prior to study dosing
  • Therapy with any approved or experimental erythropoiesis stimulating agent (ESA) within the 11 weeks prior to the Screening visit
  • Participants meeting the criteria of ESA resistance within the previous 4 months
  • Individual doses of intravenous iron of greater than 250 mg within the past 21 days
  • or alanine aminotransferase >1.8x (ULN)
  • Alkaline phosphatase >2x ULN
  • Total >1.5x ULN
  • Uncontrolled hypertension
  • Class III or IV congestive heart failure
  • Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to dosing
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    AKB-6548 240 mg

    Drug: AKB-6548

  • Experimental
    AKB-6548 370 mg

    Drug: AKB-6548

  • Experimental
    AKB-6548 500 mg

    Drug: AKB-6548

  • Experimental
    AKB-6548 630 mg

    Drug: AKB-6548

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • oral dose administered once daily for 42 days

  • DrugPlacebo

    oral Placebo administered once daily for 42 days

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6)

    Absolute change from Baseline was calculated as the Week 6 (end of treatment) value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing. If there was only one measurement prior to dosing, this measurement served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Change From Baseline in Hgb at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  2. Change From Baseline in Hematocrit (HCT) at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated HCT concentration increased.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  3. Change From Baseline in Red Blood Cell (RBC) Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated RBC count increased.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  4. Change From Baseline in Absolute Reticulocyte Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte count increased.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  5. Change From Baseline in Reticulocyte Hgb Content at Week 6

    Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte Hgb content increased.

    Time frame: Baseline, Week 6

  6. Maximum Change From Baseline in Hgb

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.

    Time frame: Baseline; up to Week 8

  7. Maximum Change From Baseline in HCT

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that HCT concentration increased.

    Time frame: Baseline; up to Week 8

  8. Maximum Change From Baseline in RBC Count

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that RBC count increased.

    Time frame: Baseline; up to Week 8

  9. Maximum Change in Absolute Reticulocyte Count From Baseline

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline absolute reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that reticulocyte count increased.

    Time frame: Baseline; up to Week 8

  10. Number of Participants With Absolute Change From Baseline in Hgb ≥ 0.4, 0.6, 0.8, and 1.0 g/dL at the End of Dosing Period

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Up to Week 6 (End of the Dosing Period)

  11. Number of Participants With Change From Baseline in Hgb ≥5.0, 7.5, and 10.0% by the End of Dosing Period

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Up to Week 6 (End of The Dosing Period)

  12. Number of Participants With Change From Baseline in HCT ≥5.0, 7.5, and 10.0% by the End of Dosing Period

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Up to Week 6 (End of The Dosing Period)

  13. Number of Participants With Change From Baseline in RBC Count ≥5.0, 7.5, and 10.0% by the End of Dosing Period

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Up to Week 6 (End of The Dosing Period)

  14. Number of Participants With Change From Baseline in Reticulocyte Count ≥6000, 12000, and 18000 Cells/uL by the End of Dosing Period

    Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline reticulocytes count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Up to Week 6 (End of The Dosing Period)

  15. Change From Baseline in Total Iron at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline total iron was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  16. Change From Baseline in Unsaturated Iron Binding Capacity at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Unsaturated Iron Binding Capacity was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  17. Change From Baseline in Iron Saturation at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron saturation was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  18. Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)

  19. Change From Baseline in Ferritin at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 2, Week 4, Week 6, Follow-up (up to Week 8)

  20. Change From Baseline in Erythropoietin at Week 2, Week 6, and Follow-up Visit (up to Week 8)

    Change from Baseline was calculated as the visit value minus the Baseline value. Baseline erythropoietin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 2, Week 6, Follow-up Visit (up to Week 8)

  21. Change From Baseline in Hepcidin at Week 6

    Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline hepcidin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

    Time frame: Baseline, Week 6

  22. Mean Plasma Vadadustat Concentrations on Week 2 and Week 4

    Plasma samples were collected for the analysis.

    Time frame: Week 2: Pre-dose and post-dose; Week 4: Pre-dose

  23. Mean Plasma Vadadustat Acyl-Glucuronide Concentrations on Week 2 and Week 4

    Plasma samples were collected for the analysis.

    Time frame: Week 2: Pre-dose; Week 4: Pre-dose

  24. Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.

    Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)

  25. Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter

    Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)

  26. Number of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. Clinical significance is determined by the investigator. The investigator was responsible for reviewing laboratory results for clinical significance.

    Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)

  27. Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval

    A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).

    Time frame: Baseline, Week 6

  28. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

    Parameters assessed for laboratory values included hematology, serum chemistry, C-reactive protein, DHEA-S, VEGF, and cystatin C. The investigator was responsible for reviewing laboratory results for clinically significant changes.

    Time frame: Up to Week 8 (Follow-up Visit 2 weeks after last dose)

07

Results

Posted Jul 1, 2022

Participant flow

Participant flow — Overall Study
MilestoneAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Started1818171919
Completed1615171818
Not completed23011
Withdrew: Adverse event12010
Withdrew: Lost to follow-up00001
Withdrew: Withdrawal of informed consent01000
Withdrew: Participant given aranesp injection10000

Outcome measures

PrimaryAbsolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6)

Absolute change from Baseline was calculated as the Week 6 (end of treatment) value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing. If there was only one measurement prior to dosing, this measurement served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.

Time frame:
Baseline, Week 6
Reported as:
Mean · Grams per deciliter (g/dL)
Absolute Change From Baseline in Hemoglobin (Hgb) to End of Treatment (Week 6)
Grams per deciliter (g/dL)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline9.46 ± 0.7929.93 ± 0.6439.86 ± 0.6069.67 ± 0.7969.83 ± 0.677
Change from Baseline at Week 60.77 ± 0.6650.73 ± 0.6231.25 ± 0.6441.43 ± 0.668-0.03 ± 0.649
Statistical analysis
  • AKB-6548 240 mg vs Placebo · Mean difference (net): 0.80 · 95% CI 0.24 to 1.35
  • AKB-6548 370 mg vs Placebo · Mean difference (net): 0.76 · 95% CI 0.20 to 1.33
  • AKB-6548 500 mg vs Placebo · Mean difference (net): 1.28 · 95% CI 0.73 to 1.83
  • AKB-6548 630 mg vs Placebo · Mean difference (net): 1.45 · 95% CI 0.91 to 2.00
  • AKB-6548 240 mg vs AKB-6548 370 mg vs AKB-6548 500 mg vs AKB-6548 630 mg vs Placebo · ANOVA · p = <0.0001
SecondaryChange From Baseline in Hgb at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · g/dL
Change From Baseline in Hgb at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
g/dLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline9.46 ± 0.7929.93 ± 0.6439.86 ± 0.6069.67 ± 0.7969.83 ± 0.677
Change from Baseline to Week 10.06 ± 0.559-0.12 ± 0.4520.28 ± 0.4390.29 ± 0.6220.04 ± 0.531
Change from Baseline to Week 20.16 ± 0.5750.00 ± 0.5900.54 ± 0.5860.53 ± 0.4550.14 ± 0.654
Change from Baseline to Week 40.54 ± 0.6590.36 ± 0.6050.85 ± 0.6501.06 ± 0.9000.08 ± 0.613
Change from Baseline to Week 60.77 ± 0.6650.73 ± 0.6231.25 ± 0.6441.43 ± 0.668-0.03 ± 0.649
Change from Baseline to Follow-up Visit (up to Week 8)0.78 ± 0.6850.40 ± 0.5531.04 ± 0.8481.01 ± 0.8720.06 ± 0.877
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9355The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6594The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0203The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0369The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3713The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1630The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7615The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0040The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0003The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3978The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0083The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0323The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0003The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4230The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0023The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0009The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5291The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0222The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9314The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Hematocrit (HCT) at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated HCT concentration increased.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · Percentage of red blood cells in blood
Change From Baseline in Hematocrit (HCT) at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Percentage of red blood cells in bloodAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline29.0 ± 2.5729.6 ± 2.4530.4 ± 2.4129.6 ± 3.6829.8 ± 1.96
Change from Baseline to Week 10.5 ± 2.280.2 ± 1.871.2 ± 1.251.6 ± 2.650.2 ± 1.70
Change from Baseline to Week 20.2 ± 2.460.1 ± 1.591.6 ± 2.331.5 ± 2.040.3 ± 2.06
Change from Baseline to Week 41.7 ± 2.370.6 ± 1.673.1 ± 2.593.4 ± 3.520.1 ± 2.34
Change from Baseline to Week 61.8 ± 2.712.1 ± 2.463.4 ± 2.474.3 ± 2.74-0.4 ± 2.40
Change from Baseline to Follow-up Visit (up to Week 8)1.9 ± 2.300.7 ± 1.902.4 ± 2.622.8 ± 3.440.0 ± 2.78
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5219The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6743The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0078The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0301The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4502The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6967The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7385The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0176The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0057The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5551The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0086The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2385The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0007The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8895The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0127The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0076The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0007The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5522The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0031The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2188The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0054The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0037The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9521The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Red Blood Cell (RBC) Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline RBC count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated RBC count increased.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · 10^6 cells/microliter (10^6 cells/μL)
Change From Baseline in Red Blood Cell (RBC) Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
10^6 cells/microliter (10^6 cells/μL)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline3.21 ± 0.4153.38 ± 0.2863.37 ± 0.2863.25 ± 0.3663.34 ± 0.463
Change from Baseline to Week 1-0.01 ± 0.185-0.07 ± 0.1780.09 ± 0.1870.04 ± 0.227-0.02 ± 0.231
Change from Baseline to Week 20.02 ± 0.183-0.05 ± 0.1860.14 ± 0.2290.11 ± 0.1720.03 ± 0.281
Change from Baseline to Week 40.16 ± 0.2130.01 ± 0.2020.26 ± 0.2510.27 ± 0.2940.02 ± 0.229
Change from Baseline to Week 60.17 ± 0.2430.18 ± 0.2730.39 ± 0.2520.41 ± 0.243-0.02 ± 0.223
Change from Baseline to Follow-up Visit (up to Week 8)0.24 ± 0.2420.06 ± 0.1990.30 ± 0.2480.26 ± 0.2730.01 ± 0.290
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3943The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2096The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0637The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5016The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7549The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5991The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4258The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0336The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0258The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2412The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0031The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7705The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0024The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0006The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6189The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0075The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0259The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8898The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0010The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2864The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0016The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9697The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Absolute Reticulocyte Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte count increased.

Time frame:
Baseline, Week 1, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · 10^6 cells/μL
Change From Baseline in Absolute Reticulocyte Count at Week 1, Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
10^6 cells/μLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline0.0766 ± 0.028550.0569 ± 0.018910.0811 ± 0.019930.0674 ± 0.027150.0700 ± 0.03319
Change from Baseline to Week 10.0022 ± 0.012790.0134 ± 0.017330.0259 ± 0.022230.0289 ± 0.031520.0010 ± 0.01677
Change from Baseline to Week 20.0012 ± 0.015050.0196 ± 0.019190.0346 ± 0.019970.0292 ± 0.01625-0.0015 ± 0.01091
Change from Baseline to Week 40.0029 ± 0.011810.0128 ± 0.015860.0234 ± 0.026850.0206 ± 0.02369-0.0023 ± 0.01636
Change from Baseline to Week 6-0.0020 ± 0.017360.0116 ± 0.023900.0061 ± 0.022170.0047 ± 0.02639-0.0004 ± 0.01788
Change from Baseline to Follow-up Visit (up to Week 8)-0.0042 ± 0.019000.0015 ± 0.02616-0.0152 ± 0.01467-0.0119 ± 0.02494-0.0035 ± 0.01522
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =1.0000The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0055The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0009The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9722The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =1.0000The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0008The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6579The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4102The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0023The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0052The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0017The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7378The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3371The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0916The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4656The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1629The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7032The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5194The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8516The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0017The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0656The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6495The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Reticulocyte Hgb Content at Week 6

Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline Reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated reticulocyte Hgb content increased.

Time frame:
Baseline, Week 6
Reported as:
Mean · Picogram
Change From Baseline in Reticulocyte Hgb Content at Week 6
PicogramAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline31.02 ± 2.94531.44 ± 2.25730.26 ± 2.60531.54 ± 2.57530.73 ± 2.634
Change From Baseline at Week 60.37 ± 0.9710.29 ± 0.7420.06 ± 0.9640.15 ± 1.2140.03 ± 1.104
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2065The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1807The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7869The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4743The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6407The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryMaximum Change From Baseline in Hgb

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that hemoglobin concentration increased.

Time frame:
Baseline; up to Week 8
Reported as:
Mean · g/dL
Maximum Change From Baseline in Hgb
g/dLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline9.46 ± 0.7929.93 ± 0.6439.86 ± 0.6069.67 ± 0.7969.83 ± 0.677
Maximum change from Baseline (up to Week 8)1.04 ± 0.5850.82 ± 0.5811.44 ± 0.6751.54 ± 0.9110.59 ± 0.568
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryMaximum Change From Baseline in HCT

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that HCT concentration increased.

Time frame:
Baseline; up to Week 8
Reported as:
Mean · Percentage of red blood cells
Maximum Change From Baseline in HCT
Percentage of red blood cellsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline29.0 ± 2.5729.6 ± 2.4530.4 ± 2.4129.6 ± 3.6829.8 ± 1.96
Maximum change from Baseline (up to Week 8)2.94 ± 2.5782.56 ± 2.0974.43 ± 2.2774.84 ± 3.4521.89 ± 1.729
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0004The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryMaximum Change From Baseline in RBC Count

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that RBC count increased.

Time frame:
Baseline; up to Week 8
Reported as:
Mean · 10^6 cells/μL
Maximum Change From Baseline in RBC Count
10^6 cells/μLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline3.21 ± 0.4153.38 ± 0.2863.37 ± 0.2863.25 ± 0.3663.34 ± 0.463
Maximum change from Baseline (up to Week 8)0.31 ± 0.2100.22 ± 0.2390.44 ± 0.2490.44 ± 0.2910.18 ± 0.183
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0043The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryMaximum Change in Absolute Reticulocyte Count From Baseline

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline absolute reticulocyte count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline. A positive change from Baseline indicated that reticulocyte count increased.

Time frame:
Baseline; up to Week 8
Reported as:
Mean · 10^6 cells/μL
Maximum Change in Absolute Reticulocyte Count From Baseline
10^6 cells/μLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline0.0766 ± 0.028550.0569 ± 0.018910.0811 ± 0.019930.0674 ± 0.027150.0700 ± 0.03319
Maximum Change from Baseline (up to Week 8)0.013 ± 0.01450.028 ± 0.01840.040 ± 0.02000.042 ± 0.02630.011 ± 0.0129
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0027The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0005The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryNumber of Participants With Absolute Change From Baseline in Hgb ≥ 0.4, 0.6, 0.8, and 1.0 g/dL at the End of Dosing Period

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Up to Week 6 (End of the Dosing Period)
Reported as:
Count of participants · Participants
Number of Participants With Absolute Change From Baseline in Hgb ≥ 0.4, 0.6, 0.8, and 1.0 g/dL at the End of Dosing Period
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Change from Baseline in Hgb ≥0.4 g/dL32212
Change from Baseline in Hgb ≥0.6 g/dL32010
Change from Baseline in Hgb ≥0.8 g/dL32310
Change from Baseline in Hgb ≥1.0 g/dL5611142
SecondaryNumber of Participants With Change From Baseline in Hgb ≥5.0, 7.5, and 10.0% by the End of Dosing Period

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline Hgb was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Up to Week 6 (End of The Dosing Period)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Hgb ≥5.0, 7.5, and 10.0% by the End of Dosing Period
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
% Change from Baseline in Hgb ≥5%43112
% Change from Baseline in Hgb ≥7.5%43310
% Change from Baseline in Hgb ≥10.0%5511142
SecondaryNumber of Participants With Change From Baseline in HCT ≥5.0, 7.5, and 10.0% by the End of Dosing Period

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline HCT was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Up to Week 6 (End of The Dosing Period)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in HCT ≥5.0, 7.5, and 10.0% by the End of Dosing Period
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
% Change from Baseline in HCT ≥5%43201
% Change from Baseline in HCT ≥7.5%10041
% Change from Baseline in HCT ≥10.0%469111
SecondaryNumber of Participants With Change From Baseline in RBC Count ≥5.0, 7.5, and 10.0% by the End of Dosing Period

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline RBC Count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Up to Week 6 (End of The Dosing Period)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in RBC Count ≥5.0, 7.5, and 10.0% by the End of Dosing Period
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
% Change from Baseline in RBCs ≥5%43231
% Change from Baseline in RBCs ≥7.5%22310
% Change from Baseline in RBCs ≥10.0%248111
SecondaryNumber of Participants With Change From Baseline in Reticulocyte Count ≥6000, 12000, and 18000 Cells/uL by the End of Dosing Period

Change from Baseline was calculated as the maximum value minus the Baseline value. Baseline reticulocytes count was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Up to Week 6 (End of The Dosing Period)
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Reticulocyte Count ≥6000, 12000, and 18000 Cells/uL by the End of Dosing Period
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Change from Baseline in Reticulocytes ≥6000 cells/uL11423
Change from Baseline in Reticulocytes ≥12000 cells/uL13031
Change from Baseline in Reticulocytes ≥18000 cells/uL25452
SecondaryChange From Baseline in Total Iron at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline total iron was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · Micrograms per deciliter (µg/dL)
Change From Baseline in Total Iron at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Micrograms per deciliter (µg/dL)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline66.0 ± 18.6877.8 ± 22.4776.1 ± 32.0160.7 ± 20.5167.6 ± 21.12
Change from Baseline to Week 2-1.8 ± 15.87-3.7 ± 18.9610.9 ± 22.9310.4 ± 24.54-4.1 ± 18.55
Change from Baseline to Week 4-1.5 ± 21.624.0 ± 16.36-1.6 ± 20.4913.2 ± 24.18-2.2 ± 20.47
Change from Baseline to Week 63.6 ± 23.262.8 ± 15.443.7 ± 25.190.7 ± 16.54-8.6 ± 25.81
Change from Baseline to Follow-up Visit (up to Week 8)-7.4 ± 19.25-7.5 ± 22.900.9 ± 31.906.2 ± 18.503.4 ± 16.05
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6051The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5197The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1073The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1321The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4358The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8109The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2575The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8361The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0294The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8809The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4971The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3994The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5022The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9916The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2292The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1331The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5518The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9032The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2387The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4251The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Unsaturated Iron Binding Capacity at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline Unsaturated Iron Binding Capacity was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · µg/dL
Change From Baseline in Unsaturated Iron Binding Capacity at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
µg/dLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline153.4 ± 34.26168.0 ± 52.46173.1 ± 56.48171.2 ± 38.77175.5 ± 33.14
Change from Baseline to Week 210.9 ± 18.7822.4 ± 19.5217.2 ± 32.1621.3 ± 27.40-1.5 ± 20.61
Change from Baseline to Week 414.4 ± 25.9626.1 ± 22.3031.5 ± 27.0837.4 ± 20.16-3.7 ± 27.89
Change from Baseline to Week 615.3 ± 30.5234.0 ± 25.6229.3 ± 16.0649.6 ± 26.50-1.3 ± 17.81
Change from Baseline to Follow-up Visit (up to Week 8)15.1 ± 30.4616.2 ± 22.74-0.7 ± 23.063.9 ± 42.200.7 ± 20.72
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0448The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0004The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0813The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0038The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6861The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0553The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0004The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7379The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0720The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6781The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0524The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0367The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6671The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6861The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9012The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Iron Saturation at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline iron saturation was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · Percentage of saturation
Change From Baseline in Iron Saturation at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Percentage of saturationAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline30.4 ± 7.5632.4 ± 9.8231.4 ± 13.3526.5 ± 10.1727.7 ± 6.60
Change from Baseline to Week 2-1.5 ± 6.26-3.8 ± 7.341.4 ± 9.150.6 ± 8.81-0.9 ± 7.86
Change from Baseline to Week 4-1.9 ± 8.10-2.3 ± 7.00-3.7 ± 7.91-0.2 ± 6.52-0.2 ± 8.65
Change from Baseline to Week 6-0.3 ± 9.24-3.8 ± 6.36-2.3 ± 7.69-4.6 ± 6.44-2.1 ± 9.09
Change from Baseline to Follow-up Visit (up to Week 8)-4.1 ± 7.08-3.9 ± 8.900.5 ± 9.941.6 ± 9.271.2 ± 5.80
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3953The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0850The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6045The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.7743The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5326The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3465The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2756The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1414The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.6941The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9403The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8310The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0654The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.4169The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0103The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3968The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0325The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2151The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.8436The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5962The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.3957The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Total Iron Binding Capacity (TIBC) at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline TIBC was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · µg/dL
Change From Baseline in Total Iron Binding Capacity (TIBC) at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
µg/dLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline219.4 ± 39.39245.8 ± 54.61249.2 ± 45.29231.8 ± 36.19243.1 ± 40.02
Change from Baseline to Week 29.2 ± 16.3418.7 ± 18.0928.1 ± 22.3231.7 ± 28.73-5.5 ± 22.51
Change from Baseline to Week 412.9 ± 24.9730.1 ± 16.2029.9 ± 24.0850.5 ± 28.64-5.9 ± 17.96
Change from Baseline to Week 618.8 ± 28.8136.8 ± 27.7633.0 ± 28.5450.3 ± 27.80-9.9 ± 25.70
Change from Baseline to Follow-up Visit (up to Week 8)7.8 ± 34.888.7 ± 18.150.2 ± 25.8210.2 ± 30.154.1 ± 23.83
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0294The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0021The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0004The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0925The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0433The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0005The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1626The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0366The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0004The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0012The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1779The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5867The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1306The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.9889The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2026The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5703The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Ferritin at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline ferritin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 2, Week 4, Week 6, Follow-up (up to Week 8)
Reported as:
Mean · Nanograms per milliliter (ng/mL)
Change From Baseline in Ferritin at Week 2, Week 4, Week 6, and Follow-up Visit (up to Week 8)
Nanograms per milliliter (ng/mL)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline349.5 ± 226.27245.8 ± 215.18332.3 ± 330.81240.2 ± 142.10200.8 ± 115.99
Change from Baseline to Week 2-66.0 ± 67.72-41.7 ± 53.18-72.0 ± 75.89-58.9 ± 54.72-12.9 ± 35.49
Change from Baseline to Week 4-69.8 ± 101.67-48.7 ± 63.08-89.6 ± 138.80-80.6 ± 64.50-20.5 ± 39.24
Change from Baseline to Week 6-65.5 ± 115.89-59.4 ± 58.76-88.9 ± 64.66-86.6 ± 62.73-19.6 ± 41.72
Change from Baseline to Follow-up Visit (up to Week 8)-50.4 ± 91.22-37.7 ± 73.31-86.1 ± 67.75-27.4 ± 107.42-20.2 ± 39.35
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0092The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0012The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1157The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0069The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0034The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0067The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0401The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0042The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0002The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0422The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0232The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0243The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.1089The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0833The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryChange From Baseline in Erythropoietin at Week 2, Week 6, and Follow-up Visit (up to Week 8)

Change from Baseline was calculated as the visit value minus the Baseline value. Baseline erythropoietin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 2, Week 6, Follow-up Visit (up to Week 8)
Reported as:
Mean · ng/mL
Change From Baseline in Erythropoietin at Week 2, Week 6, and Follow-up Visit (up to Week 8)
ng/mLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline18.011 ± 56.36084.339 ± 4.14627.287 ± 8.83338.826 ± 10.27736.963 ± 14.1425
Change from Baseline to Week 2-3.538 ± 20.31720.606 ± 3.20701.142 ± 11.8961-2.483 ± 9.5483-0.850 ± 9.3370
Change from Baseline to Week 6-3.050 ± 15.1756-1.013 ± 3.9836-3.329 ± 5.9821-0.372 ± 14.4615-1.492 ± 10.1597
Change from Baseline to Follow-up Visit (up to Week 8)-3.853 ± 15.1335-0.563 ± 5.5372-2.061 ± 6.2689-4.844 ± 9.4601-2.650 ± 8.2146
SecondaryChange From Baseline in Hepcidin at Week 6

Change from Baseline was calculated as the Week 6 value minus the Baseline value. Baseline hepcidin was defined as the average of the last two measurements obtained prior to dosing; if there was only one value prior to dosing, this value served as Baseline.

Time frame:
Baseline, Week 6
Reported as:
Mean · ng/mL
Change From Baseline in Hepcidin at Week 6
ng/mLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline326.35 ± 222.037241.03 ± 158.871242.51 ± 117.326282.75 ± 239.266258.29 ± 144.115
Change from Baseline at Week 6-28.64 ± 185.263-90.91 ± 106.826-85.01 ± 45.864-144.90 ± 184.640-32.54 ± 103.937
Statistical analysis
  • AKB-6548 240 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.5456The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 370 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0053The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 500 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = <0.0001The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • AKB-6548 630 mg · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.0040The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
  • Placebo · 2 sided t-test/Wilcoxon Signed-rank Test · p = =0.2017The comparison was made by using a 2-tailed, paired t-test (if the distribution was normal) or Wilcoxon Signed-Rank Test otherwise with an α=0.05.
SecondaryMean Plasma Vadadustat Concentrations on Week 2 and Week 4

Plasma samples were collected for the analysis.

Time frame:
Week 2: Pre-dose and post-dose; Week 4: Pre-dose
Reported as:
Mean · μg/mL
Mean Plasma Vadadustat Concentrations on Week 2 and Week 4
μg/mLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mg
Week 2 Pre-Dose4358.28 ± 2549.6236640.04 ± 5141.48410791.79 ± 9823.14312443.17 ± 17095.495
Week 2 Post-Dose17036.82 ± 8035.30821371.63 ± 8664.30439892.00 ± 19891.28441656.11 ± 20002.713
Week 4 Pre-Dose4698.21 ± 3520.5207884.56 ± 5517.13214274.80 ± 16141.43917700.17 ± 19532.648
SecondaryMean Plasma Vadadustat Acyl-Glucuronide Concentrations on Week 2 and Week 4

Plasma samples were collected for the analysis.

Time frame:
Week 2: Pre-dose; Week 4: Pre-dose
Reported as:
Mean · μg/mL
Mean Plasma Vadadustat Acyl-Glucuronide Concentrations on Week 2 and Week 4
μg/mLAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mg
Week 2 Pre-Dose1848.4 ± 979.732708.5 ± 1879.025900.1 ± 8309.246425.0 ± 7214.67
Week 4 Pre-Dose1999.3 ± 1427.742687.5 ± 2027.636866.9 ± 9247.397960.8 ± 6643.98
SecondaryNumber of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) was defined as any untoward medical occurrence (including a clinically significant abnormal laboratory finding) that occurred in the protocol-specified AE reporting period. A TEAE included medical conditions, signs, and symptoms not previously observed in the participant that emerged during the protocol-specified AE reporting period, including signs or symptoms associated with pre-existing underlying conditions that were not present prior to the AE reporting period. A SAE included AEs that met one or more of the following criteria/outcomes: death, life-threatening, in-patient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, and congenital anomaly/birth defect.

Time frame:
Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Reported as:
Count of participants · Participants
Number of Participants Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
TEAEs9681111
SAEs23111
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter

Parameters assessed for vital signs included sitting blood pressure, pulse, respiratory rate, and body temperature. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Parameter00000
SecondaryNumber of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. Clinical significance is determined by the investigator. The investigator was responsible for reviewing laboratory results for clinical significance.

Time frame:
Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Number of Participants With Clinically Significant Abnormal 12-Electrocardiogram (ECG) Findings00000
SecondaryMean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval

A standard 12-lead ECG was performed following dosing in a supine position for approximately 10 minutes. ECGs were taken prior to blood draws when possible. The parameters evaluated from the participant ECG trace included PR interval, QT interval, QRS interval, and QTc (corrected).

Time frame:
Baseline, Week 6
Reported as:
Mean · Milliseconds
Mean Change From Baseline in PR Interval, QT Interval, QRS Interval, and QT Corrected (QTc) Interval
MillisecondsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Baseline PR Interval156.7 ± 46.90174.6 ± 40.89172.8 ± 51.06187.8 ± 45.72175.8 ± 31.82
Change from Baseline PR Interval-0.8 ± 22.952.2 ± 12.3711.4 ± 29.72-11.7 ± 63.75-0.4 ± 13.07
Baseline QRS Duration94.9 ± 21.35113.8 ± 37.5797.1 ± 28.0794.5 ± 12.6594.6 ± 12.52
Change from Baseline QRS Duration4.1 ± 9.522.0 ± 13.29-1.3 ± 7.231.4 ± 10.28-1.6 ± 5.33
Baseline QT Interval412.0 ± 41.59421.4 ± 46.58419.0 ± 44.97406.9 ± 42.97419.1 ± 40.10
Change from Baseline QT Interval3.8 ± 24.787.8 ± 25.33-1.6 ± 19.834.5 ± 24.1011.0 ± 23.35
Baseline QTC Interval424.9 ± 27.70436.3 ± 37.56445.1 ± 36.10427.6 ± 23.60435.6 ± 17.90
Change from Baseline QTC Interval5.1 ± 14.333.6 ± 17.65-5.8 ± 20.70-1.6 ± 16.743.3 ± 21.46
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values

Parameters assessed for laboratory values included hematology, serum chemistry, C-reactive protein, DHEA-S, VEGF, and cystatin C. The investigator was responsible for reviewing laboratory results for clinically significant changes.

Time frame:
Up to Week 8 (Follow-up Visit 2 weeks after last dose)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values
ParticipantsAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameter Values00000

Adverse events

Collected over Up to Week 8 (Follow-up Visit 2 weeks after last dose). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AKB-6548 240 mg0/18 (0%)2/18 (11.1%)9/18 (50%)
AKB-6548 370 mg1/18 (5.6%)3/18 (16.7%)5/18 (27.8%)
AKB-6548 500 mg0/17 (0%)1/17 (5.9%)8/17 (47.1%)
AKB-6548 630 mg0/19 (0%)1/19 (5.3%)11/19 (57.9%)
Placebo0/19 (0%)1/19 (5.3%)11/19 (57.9%)
Most frequent serious events
Most frequent serious events
EventAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
DizzinessNervous system disorders0/180/181/170/190/19
Coronary artery diseaseCardiac disorders0/181/180/170/190/19
GastroenteritisInfections and infestations1/180/180/170/190/19
AzotaemiaRenal and urinary disorders0/181/180/170/190/19
Cardiac pacemaker replacementCardiac disorders1/180/180/170/190/19
Hypertensive crisisVascular disorders0/181/180/170/190/19
Fluid overloadMetabolism and nutrition disorders0/180/180/170/191/19
HypoglycaemiaMetabolism and nutrition disorders0/180/180/171/190/19
Most frequent other events
Showing 10 of 58
Most frequent other events
EventAKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlacebo
HyperkalaemiaMetabolism and nutrition disorders1/180/183/170/191/19
HypertensionVascular disorders0/180/180/172/193/19
NauseaGastrointestinal disorders1/181/182/171/192/19
Urinary tract infectionInfections and infestations2/180/181/171/190/19
HeadacheNervous system disorders2/180/180/170/190/19
AnaemiaBlood and lymphatic system disorders0/180/180/170/192/19
HypotensionVascular disorders0/180/180/170/192/19
ConstipationGastrointestinal disorders1/181/181/171/190/19
DiarrhoeaGastrointestinal disorders0/181/181/170/190/19
Frequent bowel movementsGastrointestinal disorders0/180/181/170/190/19

Baseline characteristics

Intent-to-treat (ITT) Population: All randomized participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlaceboTotal
Mean64.2 ± 12.1768.9 ± 7.8464.7 ± 9.4764.9 ± 8.7964.9 ± 9.9765.5 ± 9.69
Sex: Female, Male
Sex: Female, Male(Participants)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlaceboTotal
Female971371248
Male911412743
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlaceboTotal
Hispanic or Latino7444524
Not Hispanic or Latino111413151467
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlaceboTotal
American Indian or Alaska Native000101
Asian000101
Native Hawaiian or Other Pacific Islander010012
Black or African American6447324
White10131391459
More than one race000000
Unknown or Not Reported200114
CKD stage
CKD stage(Participants)AKB-6548 240 mgAKB-6548 370 mgAKB-6548 500 mgAKB-6548 630 mgPlaceboTotal
Stage 35445523
Stage 4131413141468
08

Study locations

28 sites
  • Pine Bluff, Arkansas, United States
  • Covina, California, United States
  • Los Angeles, California, United States
  • Lynwood, California, United States
  • Riverside, California, United States
  • San Dimas, California, United States
  • Whittier, California, United States
  • Coral Springs, Florida, United States
  • Lauderdale Lakes, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Augusta, Georgia, United States
  • Macon, Georgia, United States
  • Wichita, Kansas, United States
  • Shreveport, Louisiana, United States
  • Springfield, Massachusetts, United States
  • Detroit, Michigan, United States
  • Pontiac, Michigan, United States
  • Warren, Michigan, United States
  • Bethpage, New York, United States
  • Mineola, New York, United States
  • Wilmington, North Carolina, United States
  • Oklahoma City, Oklahoma, United States
  • Knoxville, Tennessee, United States
  • Austin, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Am J Nephrol. 2017;45(5):380-388. doi: 10.1159/000464476. Epub 2017 Mar 25. PubMed 28343225 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2011 to primary completion in Feb 2012, 8 months.

Results were first posted in Jul 2022, 10 years 4 months after primary completion. A results delay was requested in Oct 2012.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 8 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2011
First posted
Jun 27, 2011
StartActual
Jun 15, 2011
Primary completionActual
Feb 16, 2012
CompletionActual
Feb 16, 2012
Results delay requested
Oct 3, 2012
Results first posted
Jul 1, 2022
Last update
Jul 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01381094
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Jun 15, 2011
Primary completion
Feb 16, 2012
Completion
Feb 16, 2012
Results posted
Jul 1, 2022
Last update
Jul 1, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion